Arch Therapeutics, Inc. ('Arch' or the 'Company') announced that it has launched a multi-site clinical study (the 'Study') to accelerate payor adoption and differentiate the key benefits of AC5® Advanced Wound System ('AC5') in treating challenging wounds. The Study is expected to enroll and treat up to 60 patients at six sites with a primary end point of wound closure. The launch of the Study completes the near-term commitments listed in the Company's recently announced reimbursement initiative to accelerate sales opportunities for AC5 in doctor's offices and wound care clinics.